about
Decreased expression of prenyl diphosphate synthase subunit 2 correlates with reduced survival of patients with gastric cancerSerosal invasion strongly associated with recurrence after curative hepatic resection of hepatocellular carcinoma: a retrospective study of 214 consecutive cases.Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors.Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue.Correlation Between Poor Prognosis and Lower TPPP Gene Expression in Hepatocellular Carcinoma.Search for useful biomarkers in hepatocellular carcinoma, tumor factors and background liver factors (Review).Epigenetic modulation associated with carcinogenesis and prognosis of human gastric cancer.Prognostic Value of Long Non-Coding RNA HULC and MALAT1 Following the Curative Resection of Hepatocellular Carcinoma.Genome-wide Discovery of a Novel Gene-expression Signature for the Identification of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma.Association of Inflammasome Components in Background Liver with Poor Prognosis After Curatively-resected Hepatocellular Carcinoma.High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis.Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image ClassificationIt Takes Two to Tango: Immune Cells and Tumor-Associated Stroma as Prognostic Biomarkers in Pancreatic Ductal AdenocarcinomaIdentification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapyA genomewide transcriptomic approach identifies a novel gene expression signature for the detection of lymph node metastasis in patients with early stage gastric cancerPhase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study.[A case of anaphylactic shock caused by granisetron]Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinomaA comprehensive methylation signature identifies lymph node metastasis in esophageal squamous cell carcinomaMelatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cellsClinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic CancerClinical impact of additional therapy for residual pancreatic cancerNovel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic CancerPerioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinomaComparison of non-invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinomaBiological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancerClinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic CancerIntratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell CarcinomaNovel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimensEffects of duration of initial treatment on postoperative complications in pancreatic cancerTumour Marker Recovery rather than Major Pathological Response is a Preferable Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma with Preoperative Therapy
P50
Q34402115-D740A2B2-1AC7-4516-9CD0-8F44BCD7326CQ36008924-2BDAA632-9A1B-4223-A2B9-FD21EFA5CDEAQ37407115-0D1172DD-1CBB-4034-BA95-1E2063F4E2B4Q37582227-721D3354-327F-415C-A077-2CCB14CE6AC5Q38746175-BCDB8460-912B-4E53-95E8-78A59DF127B9Q39230841-82396070-B559-4918-999E-7373F640B66BQ39321339-EBFF057F-1BA2-4D34-B5BE-9DAB8E887554Q47171682-3A1A6D72-1B91-46E9-9BEC-F6E4FE659B0AQ47311325-D85767DB-B19C-41AB-9B74-255F19F7CBAEQ50992222-E0E27952-57E2-4CDF-93D0-4028D1129BEFQ54184067-446EB965-546D-49B1-A603-AC15E059B2CCQ55516060-F641542C-3A18-4196-B8B5-86FB20634660Q57040455-0FC01311-986C-4E2D-A07D-8AF909C49C50Q57296912-6C60E730-9CD5-466B-9B15-787DCAC84CACQ60921707-94AD2B39-9133-4062-AB9B-A06F6584EBEFQ64286762-182D3651-1DEC-4FE3-AB25-CCF900A83952Q64990637-6D1EB00D-E0D5-4127-8132-8F58E88475CCQ81311363-8ECA0EFE-1DFF-4C86-A415-D237666DF3C9Q85252027-3485F938-1A87-4D2A-BFDC-77D3FCFF806EQ90157754-8F16C6A8-0207-4B7A-AB09-94FD25150731Q90779062-178E3032-14DB-422C-8D12-BB9398CD4749Q90880647-F299A4AD-B1F1-48E9-BA19-842C461F299EQ90934020-3FBEAADD-5DD9-4899-A9CA-C132FF0E7DDAQ91049444-D1B17F1A-2CB4-4998-B49D-C532497A54E2Q91273882-BE82781F-78BA-4231-87C7-19DE04686A23Q91510030-D2966071-B619-45BA-90BF-C083DE9B1A80Q91656698-5FDE17A5-18CB-4439-A44E-55DBB1F4C387Q92062627-5A8CEAFD-E2F8-448B-BEA8-AD4EB016421EQ92264245-73BF4ABB-F5C8-4E27-BAA4-D73928BCBED2Q92416047-DD0065BE-E71B-4479-8AE2-00685B514AACQ92666389-55C4CBF3-9C98-410B-8D2C-F528E027C8E7Q94486614-1EC6656E-59A3-4FB1-A08A-AE998081FD26
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fuminori Sonohara
@ast
Fuminori Sonohara
@en
Fuminori Sonohara
@es
Fuminori Sonohara
@nl
Fuminori Sonohara
@sl
type
label
Fuminori Sonohara
@ast
Fuminori Sonohara
@en
Fuminori Sonohara
@es
Fuminori Sonohara
@nl
Fuminori Sonohara
@sl
prefLabel
Fuminori Sonohara
@ast
Fuminori Sonohara
@en
Fuminori Sonohara
@es
Fuminori Sonohara
@nl
Fuminori Sonohara
@sl
P106
P31
P496
0000-0001-6438-2122